SOX2 and neoplasm: In contrast, in non-responder patients all primary tumours stained positive for Sox2 (22 patients); furthermore, there was a significant increase in Sox2 expression in the recurrent lesions (26 samples, since four of them recurred twice), compared with the matched primary tumours.